Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized channelopathy-guided drug treatment in developmental and epileptic encephalopathies due to potassium channel mutations
2020-005908-18Phase 2Completed
- Sponsor
- Policlinico Federico II
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gabapentin, fluoxetine, metformin, amitriptyline and dalfampridine in epileptic encephalopathy, epilepsy and Autism Spectrum Disorder (ASD) (5 arms), sponsored by Policlinico Federico II. Started Jun 2021; status: completed.
02
Drugs
gabapentinfluoxetinemetforminamitriptylinedalfampridine
03
Conditions
epileptic encephalopathyepilepsyAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2020-005908-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005908-18.